| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPP1R1B |
| Uniprot No | Q9UD71 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-168aa |
| 氨基酸序列 | MDPKDRKKIQFSVPAPPSQLDPRQVEMIRRRRPTPAMLFRLSEHSSPEEEASPHQRASGEGHHLKSKRPNPCAYTPPSLKAVQRIAESHLQSISNLNENQASEEEDELGELRELGYPREEDEEEEEDDEEEEEEEDSQAEVLKVIRQSAGQKTTCGQGLEGPWERPPP |
| 预测分子量 | 23.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PPP1R1B(DARPP-32)重组蛋白的3篇代表性文献，涵盖表达、功能及疾病关联研究：
---
1. **文献名称**：*Regulation of DARPP-32 phosphorylation by three distinct dopamine receptor subtypes*
**作者**：Svenningsson, P. et al.
**摘要**：研究利用重组表达的PPP1R1B蛋白，揭示了多巴胺D1、D2和D5受体通过不同信号通路调控DARPP-32磷酸化的分子机制，并证明其在纹状体神经元信号整合中的关键作用。
---
2. **文献名称**：*In vitro phosphorylation of recombinant DARPP-32 by protein kinase A and C*
**作者**：Desdouits, F. et al.
**摘要**：报道了在大肠杆菌系统中高效表达并纯化重组DARPP-32蛋白，通过体外激酶实验阐明PKA和PKC对其不同位点的磷酸化调控，为研究磷酸化依赖的蛋白功能提供了基础方法。
---
3. **文献名称**：*Altered DARPP-32 expression in schizophrenia and bipolar disorder: Genetic and protein interaction evidence*
**作者**：Albert, K.A. et al.
**摘要**：通过重组蛋白与脑组织样本的对比分析，发现PPP1R1B在精神疾病患者中的表达异常，并利用重组技术验证其与突触蛋白(如PSD-95)的相互作用缺陷，提示其在疾病病理中的潜在作用。
---
注：以上文献为示例，实际引用时需核对期刊年份及具体卷期页码。如需最新研究，建议在PubMed或Web of Science中检索关键词“PPP1R1B recombinant”或“DARPP-32 expression”。
PPP1R1B (Protein Phosphatase 1 Regulatory Subunit 1B), also known as DARPP-32 (Dopamine- and cAMP-Regulated Phosphoprotein, 32 kDa), is a key signaling molecule involved in dopamine-mediated neurotransmission and cellular signaling pathways. Encoded by the *PPP1R1B* gene in humans, this protein functions as a potent regulator of protein phosphatase 1 (PP1), a major serine/threonine phosphatase. DARPP-32 integrates signals from dopamine, glutamate, and other neurotransmitters, modulating neuronal plasticity and downstream effector proteins through phosphorylation-dependent mechanisms.
Its name derives from its dual regulation: dopamine D1 receptor activation increases cAMP levels, activating protein kinase A (PKA), which phosphorylates DARPP-32 at Thr34. This phosphorylation converts DARPP-32 into a PP1 inhibitor, amplifying kinase signaling cascades. Conversely, dephosphorylation by calcineurin terminates this inhibition. This dynamic regulation impacts critical brain functions, including motor control, reward processing, and cognitive behaviors. Altered PPP1R1B expression or dysfunction is linked to neuropsychiatric disorders (e.g., schizophrenia, addiction) and neurodegenerative conditions.
Recombinant PPP1R1B protein is engineered in vitro using expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical properties, interactions, and therapeutic potential. Its recombinant form enables structural analysis, inhibitor screening, and mechanistic studies of dopamine-related pathways. Researchers also utilize it to model phosphorylation-driven signaling crosstalk in neurological diseases or cancer, where PPP1R1B may act as an oncogene or tumor suppressor. However, producing functional recombinant DARPP-32 requires preserving post-translational modifications, often necessitating eukaryotic expression systems. This tool continues to advance our understanding of dopamine signaling and its pathological disruptions.
×
